Dr. Wenwu Zhai, currently SVP & CSO, brings more than 20 years of expertise in antibody and protein drug discovery and development from target identification, lead selection and preclinical studies to IND filling. Before joining Staidson Bio, he worked in world renowned pharmaceutical companies of Pfizer Inc, Genentech, NGM Biopharmaceuticals, and research institution of UCSF. As a team leader, he has directly participated and contributed to the successful development of several antibody drugs. He is the co-inventor of more than 20 antibody therapeutic patents, and co-author of over 30 scientific publications. Dr Zhai received his PhD in Molecular Biology from University of Manchester, and did his postdoctoral training in Antibody Engineering from MRC center, University of Cambridge, UK.